ReviewExperimental brain research2019
5-HT
Review in Experimental brain research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 28 citations in OpenAlex.
- Neurophysiological Treatment Effects of Mesdopetam, Pimavanserin and Amantadine in a Rodent Model of Levodopa-Induced Dyskinesia.The European journal of neuroscience · 2025Article
- Positive allosteric mGluRNaunyn-Schmiedeberg's archives of pharmacology · 2024Article
- [Experimental brain research · 2024Article
- Effect of the mGluPsychopharmacology · 2023Article
- Pimavanserin and Parkinson's Disease Psychosis: A Narrative Review.Brain sciences · 2022Review
- Evaluation of the effects of the mGluPharmacological reports : PR · 2022Article
- Additive effects of mGluRNaunyn-Schmiedeberg's archives of pharmacology · 2021Article
- Further characterisation of psychosis-like behaviours induced by L-DOPA in the MPTP-lesioned marmoset.Naunyn-Schmiedeberg's archives of pharmacology · 2021Article
- Effect of the mGluJournal of neural transmission (Vienna, Austria : 1996) · 2021Article
- Monoamine oxidase A inhibition with moclobemide enhances the anti-parkinsonian effect of L-DOPA in the MPTP-lesioned marmoset.Naunyn-Schmiedeberg's archives of pharmacology · 2020Article
- Monoamine oxidase A inhibition as monotherapy reverses parkinsonism in the MPTP-lesioned marmoset.Naunyn-Schmiedeberg's archives of pharmacology · 2020Article
- Combined mGluJournal of neural transmission (Vienna, Austria : 1996) · 2020Article
- The mGluJournal of neural transmission (Vienna, Austria : 1996) · 2020Article
- Interactions Between the Serotonergic and Other Neurotransmitter Systems in the Basal Ganglia: Role in Parkinson's Disease and Adverse Effects of L-DOPA.Frontiers in neuroanatomy · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Virtually every patient affected by Parkinson's disease (PD) eventually requires treatment with L-3,4-dihydroxyphenylalanine (L-DOPA), which leads to complications such as dyskinesia and psychosis. Whereas blockade of serotonin 2A (5-HT
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.